Soligenix Inc. (NASDAQ: SNGX) announced that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion for orphan drug designation of dusquetide (SGX945) for the treatment of Behcet's disease. The designation is a significant regulatory milestone that could accelerate development of the innate defense regulator for this rare inflammatory condition.
The positive opinion from the COMP is expected to lead to formal orphan drug designation by the European Commission. This status provides incentives including protocol assistance, reduced regulatory fees, and up to 10 years of market exclusivity following approval. For patients with Behcet's disease, a chronic condition characterized by inflammation of blood vessels throughout the body, this regulatory progress represents a potential step toward a new therapeutic option.
Christopher J. Schaber, PhD, CEO and president of Soligenix, stated, "We are extremely pleased to have received the positive opinion from the COMP and look forward to the European Commission granting the orphan drug designation for the SGX945 program." He noted that Behcet's disease remains an area of significant unmet medical need.
Dusquetide is classified as an innate defense regulator, a novel class of compounds designed to modulate the body's innate immune system rather than suppress it directly. This mechanism could offer advantages over traditional immunosuppressive therapies for inflammatory diseases. Soligenix is advancing the program through clinical development, and the orphan designation may help streamline the regulatory pathway in Europe.
For companies focused on rare diseases, orphan drug designations from regulatory agencies can provide critical support. The EMA's positive opinion validates the scientific rationale behind dusquetide and may enhance Soligenix's ability to attract partnerships or funding. The company is also pursuing development in the United States, where similar orphan drug status could be sought from the FDA.
Behcet's disease affects approximately 1 in 5,000 people in Japan and 1 in 500,000 in the United States, though prevalence varies by region. Symptoms can include oral and genital ulcers, skin lesions, and eye inflammation. Current treatments often rely on corticosteroids and immunosuppressants, which carry significant side effects. An innate defense regulator like dusquetide could offer a new approach by harnessing the body's natural immune defenses.
Soligenix continues to evaluate dusquetide in clinical trials. The company's newsroom provides updates on the program at https://ibn.fm/SNGX. The positive EMA opinion marks a key step forward for both the company and patients awaiting new therapies for Behcet's disease.
